We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Excimer Laser Ablation Successfully Treats Peripheral Artery Disease

By HospiMedica International staff writers
Posted on 26 Jan 2010
A laser treatment for peripheral artery disease (PAD) reduces stenosis diameter by over 30% immediately following treatment, according to a new study.

Researchers at Harrisburg Hospital (PA, USA) conducting the CLiRpath Excimer Laser System to Enlarge Lumen Openings (CELLO) study enrolled 65 patients with claudication, or walking impairments caused by PAD. More...
Laser-assisted recanalization with optional balloon angioplasty (BA) or BA + stenting were performed on superficial femoral and popliteal arteries that were at least 70% blocked. The primary endpoint was the reduction in index lesion-percent diameter stenosis (%DS) as measured by Doppler ultrasound. The primary safety endpoint was major adverse events at 6 months.

The results showed that laser ablation reduced the %DS from a median 77% at baseline to 34.7%, which was further reduced to 21% after adjunctive therapy with BA or BA + stenting; 8 (12.3%) patients did not receive post laser adjunctive therapy. There were no major adverse events, and target lesion revascularization was not required in 76.9% of the participants within the one-year follow-up. The study cohort demonstrated a statistically significant improvement in the walking impairment and functional status assessments during follow-up. In all, the study met its primary endpoint by reducing, on average, the percent diameter stenosis from 77.3% to 42.5% immediately post treatment. The study was published in the December 2009 issue of the Journal of Endovascular Therapy.

"Preventing the millions of leg amputations caused by PAD represents an urgent medical imperative,” said lead author Rajesh Dave, M.D. "This study demonstrated the Turbo-Booster's ability to produce larger lumens than what was previously achieved by excimer laser catheters alone. This may help reduce the need for aggressive adjunctive therapy, like stenting.”

The researchers used the Spectranetics (Colorado Springs, CO, USA) Turbo-Booster for the excimer laser-ablation procedures. The treatment delivers pulsed bursts of ultraviolet (UV) energy that vaporizes blockages into tiny particles that are easily dissolved into the bloodstream. In contrast to the long recovery time required for bypass surgery, the excimer laser ablation procedure is performed within one to two hours with only minutes of laser time, followed by one to two days of recovery. Patients typically experience very little, if any, discomfort during the procedure.

Related Links:
Harrisburg Hospital
Spectranetics



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.